Targeting cancer with
Power+Precision tm

Welcome to Viventia Bio Inc.

Broad, Clinical-Stage Oncology Pipeline

Viventia is advancing a broad pipeline of Targeted Protein Therapeutics (TPTs), which are fully biologic fusion constructs containing antibody fragments, “Precision,” combined using a proprietary linker with protein toxin payloads “Power.”

Advanced Product Candidates

Viventia’s most advanced product candidates include ViciniumTM for the treatment of high-grade non-muscle invasive bladder cancer and ProxiniumTM for the treatment of late-stage squamous cell carcinoma of the head and neck.

Robust Platform

Viventia has additional early stage products in development that use its TPT technology platform which we expect to begin evaluating in clinical trials in 2016.